Drug giant calls for clarity on Brexit and minimum two-year transition period to avoid disruption to medical supplies …
“The company is not planning to move operations out of the UK, but if no deal is reached, it will duplicate certain facilities in Europe, allowing it to retest drugs manufactured in Britain and shipped to the continent.
Walmsley said, “We are not thinking of any relocation out of the UK, but … we are looking at contingency planning in terms of testing facilities, to allow us to have as seamless a transition as possible, and make sure we are providing secure supply to the patients that need our drugs and medicines.”
She added, “All of that work is under way in the detailed planning group, and we will be ready for it as necessary.”
GlaxoSmithKline’s requests to the government also include making sure the UK can participate in the EU regulatory framework, setting up a talent-friendly immigration policy and delivering predictable funding levels for UK sciences.”